FUS R521C

# Research Brief: FUS R521C Variant ## Pathogenic Mechanisms The FUS R521C variant represents a pathogenic mutation in the PY-nuclear localization signal (NLS) domain of the FUS protein, a critical RNA-binding protein involved in DNA damage response, transcriptional regulation, and RNA processing. This variant disrupts the normal nuclear import mechanism, leading to cytoplasmic mislocalization and subsequent aggregation of FUS protein. The mutation affects a protein with known functions in chromatin binding, DNA binding, and identical protein binding, while participating in critical biological processes including amyloid fibril formation and membraneless organelle assembly through liquid-liquid phase separation. The R521C substitution compromises the electrostatic interactions necessary for efficient nuclear import mediated by transportin-1, resulting in cytoplasmic accumulation where FUS forms pathological inclusions characteristic of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The propensity for amyloid fibril formation, combined with impaired nuclear-cytoplasmic trafficking, creates a toxic gain-of-function mechanism that disrupts RNA metabolism and stress granule dynamics. ## Clinical Significance The FUS R521C variant is classified as a moderate-severity mutation associated with ALS/FTD spectrum disorders. Positioned within the critical PY-NLS domain (residues 514-526), this variant represents one of several pathogenic mutations in this region that cause familial ALS with variable penetrance and age of onset. The arginine-to-cysteine substitution at position 521 represents a significant biochemical change, replacing a positively charged, hydrophilic residue with a neutral, sulfur-containing amino acid, fundamentally altering the protein's ability to interact with nuclear import machinery. Clinical manifestations typically include progressive motor neuron degeneration, though phenotypic variability exists among carriers, suggesting potential modifying genetic or environmental factors. ## Therapeutic Landscape Structural analysis has identified a key aggregation hotspot at residues 307-311 (aggregation score: 0.54), representing a promising therapeutic target. The candidate peptide CP-FUS-001 has been computationally designed to specifically target this aggregation-prone region, with the rationale of interfering with pathological FUS self-assembly while preserving normal protein function. This peptide inhibitor approach aims to prevent the formation of cytoplasmic aggregates that characterize FUS proteinopathy. The targeting of residues 307-311 is strategically positioned within the low-complexity domain of FUS, which drives phase separation and aggregation. Current therapeutic strategies would benefit from experimental validation of CP-FUS-001's efficacy in cellular and animal models, alongside exploration of small molecule modulators that could restore nuclear localization or enhance clearance of cytoplasmic FUS aggregates. ## Research Directions Critical knowledge gaps remain regarding genotype-phenotype correlations for R521C compared to other PY-NLS mutations, necessitating comprehensive natural history studies and patient registries. Priority research directions include: (1) validating CP-FUS-001 in patient-derived induced pluripotent stem cells (iPSCs) and neuronal models; (2) investigating whether nuclear import enhancers or autophagy modulators can reduce cytoplasmic FUS burden; (3) characterizing protein-protein interactions disrupted by R521C, particularly with known interactors TARDBP, SAFB, TAF15, RBMX, and RALY; and (4) exploring biomarkers for early detection and progression monitoring in R521C carriers. Additionally, cross-variant comparisons with other FUS mutations could reveal common therapeutic vulnerabilities across the ALS/FTD spectrum.